Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Guérin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-naïve High-grade Non-muscle-invasive Bladder Cancer (BRIDGE).

Max Kates, Xiangying Chu,Noah Hahn,Eugene Pietzak,Angela Smith,Daniel H Shevrin,Paul Crispen,Stephen B Williams,Siamak Daneshmand,Vignesh T Packiam,Sima Porten,Mary E Westerman,Lynne I Wagner,Michael Carducci

European urology focus（2023）

引用 1|浏览15

暂无评分

摘要

EA8212 BRIDGE is a phase 3 randomized trial comparing BCG vs GemDoce for BCG naïve high-risk non-muscle-invasive bladder cancer. This article provides an explanation for the rationale of the clinical trial and details the study design.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要